Craig Lustig, MPA, describes how healthcare providers who nurture hope in their cancer care approach can offer clinical benefits and unique advantages to patients.
Combining radiotherapy-based, metastasis-directed therapy with hormone therapy led to better progression-free survival for patients with oligometastatic prostate cancer.
Despite promising results from preclinical work and a small earlier trial, the drug failed to improve function in this underdiagnosed and often undertreated population.
Intuitive monitor featuring patient-tailored approach is now in clinical use in select centers in U.S. and Europe LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company